At Xylyx Bio, we have developed IN MATRICO™ Fibrosis Assay that incorporates our human derived, disease-specific extracellular matrices as well as corresponding data analytics for anti-fibrotic drug discovery. Our IN MATRICO™ Fibrosis Assay is applicable across multiple stages of the early-stage drug discovery pipeline, from target selection and hit identification through lead identification and optimization.
Read press releaseView webinar
Accelerate and improve drug discovery and screening in IPF with custom IPF-specific ECM substrates, allowing drug candidates to be studies in a human, disease-relevant environment in vitro.
Implement custom NASH-derived ECM substrates into preclinical human disease models and cell-based screening assays to increase clinical relevance and success rates.